51 related articles for article (PubMed ID: 38734383)
1. Sodium taurocholate cotransporting polypeptide (NTCP) polymorphisms may influence HDV RNA load and early response to bulevirtide.
Toniutto P; Falleti E; Cmet S; Cussigh A; Degasperi E; Anolli MP; Sambarino D; Facchetti F; Borghi M; Perbellini R; Monico S; Lampertico P
J Hepatol; 2024 Jun; ():. PubMed ID: 38901675
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial.
Wedemeyer H; Schöneweis K; Bogomolov P; Blank A; Voronkova N; Stepanova T; Sagalova O; Chulanov V; Osipenko M; Morozov V; Geyvandova N; Sleptsova S; Bakulin IG; Khaertynova I; Rusanova M; Pathil A; Merle U; Bremer B; Allweiss L; Lempp FA; Port K; Haag M; Schwab M; Zur Wiesch JS; Cornberg M; Haefeli WE; Dandri M; Alexandrov A; Urban S
Lancet Infect Dis; 2023 Jan; 23(1):117-129. PubMed ID: 36113537
[TBL] [Abstract][Full Text] [Related]
3. Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D.
Asselah T; Chulanov V; Lampertico P; Wedemeyer H; Streinu-Cercel A; Pântea V; Lazar S; Placinta G; Gherlan GS; Bogomolov P; Stepanova T; Morozov V; Syutkin V; Sagalova O; Manuilov D; Mercier RC; Ye L; Da BL; Chee G; Lau AH; Osinusi A; Bourliere M; Ratziu V; Pol S; Hilleret MN; Zoulim F; Didier S
N Engl J Med; 2024 Jun; ():. PubMed ID: 38842520
[TBL] [Abstract][Full Text] [Related]
4. Advances in hepatitis delta research: emerging insights and future directions.
Degasperi E; Anolli MP; Lampertico P
Sex Transm Infect; 2024 Jun; ():. PubMed ID: 38914473
[TBL] [Abstract][Full Text] [Related]
5. Characterizing Hepatitis Delta in Spain and the gaps in its management.
Rodríguez-Tajes S; Palom A; Giráldez Gallego Á; Moreno A; José Urquijo J; Rodríguez M; Alvarez-Argüelles M; Diago M; García-Eliz M; Fuentes J; Sapiña Pérez AMM; Castillo P; Casado M; Pérez Campos E; Muñoz R; Hernández-Conde M; María Morillas R; Granados R; Miquel M; Morillas Ariño MJ; García-Retortillo M; Antonio Carrión J; María Moreno J; Montón C; González-Santiago JM; Lorente S; Cabezas J; Mateos B; Vázquez-Rodríguez S; Díaz-Fontenla F; María Pinazo J; Delgado M; Pérez-Palacios D; Horta D; Fernández Marcos C; López C; Luis Calleja J; Fernández I; García-Samaniego J; Forns X; Buti M; Lens S
Gastroenterol Hepatol; 2024 Jun; ():502222. PubMed ID: 38908682
[TBL] [Abstract][Full Text] [Related]
6. Autoimmune Hepatitis Induced by Hepatitis Delta Virus: A Conundrum.
Cardoso MF; Carvalho R; Correia FP; Branco JC; Costa MN; Martins A
GE Port J Gastroenterol; 2024 Jun; 31(3):203-208. PubMed ID: 38836124
[TBL] [Abstract][Full Text] [Related]
7. Bulevirtide for patients with compensated chronic hepatitis delta: A review.
Degasperi E; Anolli MP; Lampertico P
Liver Int; 2023 Aug; 43 Suppl 1():80-86. PubMed ID: 35942695
[TBL] [Abstract][Full Text] [Related]
8. Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy.
Soriano V; Moreno-Torres V; Treviño A; Corral O; de Mendoza C
Drug Des Devel Ther; 2023; 17():155-166. PubMed ID: 36712949
[TBL] [Abstract][Full Text] [Related]
9. No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta.
Hollnberger J; Liu Y; Xu S; Chang S; Martin R; Manhas S; Aeschbacher T; Han B; Yazdi T; May L; Han D; Shornikov A; Flaherty J; Manuilov D; Suri V; Asselah T; Lampertico P; Wedemeyer H; Aleman S; Richards C; Mateo R; Maiorova E; Cihlar T; Mo H; Urban S
J Hepatol; 2023 Sep; 79(3):657-665. PubMed ID: 37120031
[TBL] [Abstract][Full Text] [Related]
10. Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies.
Allweiss L; Volmari A; Suri V; Wallin JJ; Flaherty JF; Manuilov D; Downie B; Lütgehetmann M; Bockmann JH; Urban S; Wedemeyer H; Dandri M
J Hepatol; 2024 Jun; 80(6):882-891. PubMed ID: 38340811
[TBL] [Abstract][Full Text] [Related]
11. Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension.
Degasperi E; Anolli MP; Uceda Renteria SC; Sambarino D; Borghi M; Perbellini R; Scholtes C; Facchetti F; Loglio A; Monico S; Fraquelli M; Costantino A; Ceriotti F; Zoulim F; Lampertico P
J Hepatol; 2022 Dec; 77(6):1525-1531. PubMed ID: 35973578
[TBL] [Abstract][Full Text] [Related]
12. Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life.
Asselah T; Loureiro D; Le Gal F; Narguet S; Brichler S; Bouton V; Abazid M; Boyer N; Giuly N; Gerber A; Tout I; Maylin S; Bed CM; Marcellin P; Castelnau C; Gordien E; Mansouri A
Liver Int; 2021 Jul; 41(7):1509-1517. PubMed ID: 33999515
[TBL] [Abstract][Full Text] [Related]
13. Modelling HDV kinetics under the entry inhibitor bulevirtide suggests the existence of two HDV-infected cell populations.
Shekhtman L; Cotler SJ; Degasperi E; Anolli MP; Uceda Renteria SC; Sambarino D; Borghi M; Perbellini R; Facchetti F; Ceriotti F; Lampertico P; Dahari H
JHEP Rep; 2024 Feb; 6(2):100966. PubMed ID: 38274491
[TBL] [Abstract][Full Text] [Related]
14. Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase 3 randomized trial.
Wedemeyer H; Aleman S; Brunetto M; Blank A; Andreone P; Bogomolov P; Chulanov V; Mamonova N; Geyvandova N; Morozov V; Sagalova O; Stepanova T; Berger A; Ciesek S; Manuilov D; Mercier RC; Da BL; Chee GM; Li M; Flaherty JF; Lau AH; Osinusi A; Schulze Zur Wiesch J; Cornberg M; Zeuzem S; Lampertico P
J Hepatol; 2024 May; ():. PubMed ID: 38734383
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
